Apyx Medical Corporation Reports Preliminary, Unaudited, Fourth Quarter and Full Year 2025 Revenue Results

Rhea-AI Summary

Apyx Medical (Nasdaq: APYX) reported preliminary, unaudited revenue for Q4 and full year 2025. Q4 2025 total revenue is expected to be approximately $19.0–$19.2M (+~34% YoY), driven by Surgical Aesthetics of $16.6–$16.8M (+~38% YoY) and OEM revenue of ~$2.4M (+~13% YoY). Apyx cited a U.S. Surgical Aesthetics increase of ~51% following the AYON commercial launch. For full year 2025, total revenue is expected at $52.7–$52.9M (+~10% YoY), Surgical Aesthetics $45.2–$45.4M (+~17% YoY), and OEM ~$7.5M (−21% YoY). The company will release audited results in March 2026; figures are preliminary and subject to closing and audit procedures.

Positive

• Q4 total revenue expected +34% year-over-year to $19.0–$19.2M
• Q4 Surgical Aesthetics revenue expected +38% year-over-year to $16.6–$16.8M
• Full-year 2025 Surgical Aesthetics revenue expected +17% to $45.2–$45.4M
• U.S. Surgical Aesthetics revenue increased approximately 51% after AYON launch

Negative

• Full-year 2025 OEM revenue expected −21% year-over-year to ~$7.5M

News Market Reaction

+14.90% 3.2x vol

15 alerts

+14.90% News Effect

+7.7% Peak in 6 hr 29 min

+$21M Valuation Impact

$166M Market Cap

3.2x Rel. Volume

On the day this news was published, APYX gained 14.90%, reflecting a significant positive market reaction. Argus tracked a peak move of +7.7% during that session. Our momentum scanner triggered 15 alerts that day, indicating notable trading interest and price volatility. This price movement added approximately $21M to the company's valuation, bringing the market cap to $166M at that time. Trading volume was very high at 3.2x the daily average, suggesting strong buying interest.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Q4 2025 total revenue: $19.0–$19.2M Q4 2025 Surgical Aesthetics: $16.6–$16.8M Q4 2025 OEM revenue: $2.4M +4 more

7 metrics

Q4 2025 total revenue $19.0–$19.2M Preliminary range, ~34% year-over-year increase

Q4 2025 Surgical Aesthetics $16.6–$16.8M Preliminary, ~38% year-over-year increase

Q4 2025 OEM revenue $2.4M Preliminary, ~13% year-over-year increase

FY 2025 total revenue $52.7–$52.9M Preliminary, ~10% year-over-year increase

FY 2025 Surgical Aesthetics $45.2–$45.4M Preliminary, ~17% year-over-year increase

FY 2025 OEM revenue $7.5M Preliminary, 21% year-over-year decrease

U.S. Surgical Aesthetics growth 51% Approximate Q4 2025 year-over-year increase in the U.S.

Market Reality Check

Price: $3.97 Vol: Volume 26,538 vs 20-day a...

low vol

$3.97 Last Close

Volume Volume 26,538 vs 20-day average 49,825 (relative volume 0.53), indicating lighter-than-normal trading ahead of the news. low

Technical Shares at $3.49 were trading above the $2.36 200-day MA and about 21.4% below the 52-week high of $4.44.

Peers on Argus

APYX was up about 0.87% while key medical device peers like XTNT, LUNG, BDMD, an...

1 Down

APYX was up about 0.87% while key medical device peers like XTNT, LUNG, BDMD, and TELA showed declines between roughly 0.9% and 3%, pointing to a stock-specific setup rather than a broader sector move.

Historical Context

5 past events · Latest: Dec 03 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Dec 03	Intl launch/approval	Positive	-1.7%	MFDS approval and commercial launch of Apyx One in South Korea.
Nov 18	Equity offering priced	Negative	-5.5%	Pricing of $10M underwritten public offering of common stock.
Nov 17	Equity offering proposed	Negative	+3.3%	Announcement of proposed underwritten public offering from existing shelf.
Nov 06	Earnings update	Positive	+6.7%	Q3 2025 results with revenue growth, margin expansion, narrowed losses.
Oct 27	Investor conferences	Neutral	-2.5%	Planned participation in November investor conferences in New York.

Pattern Detected

The stock has tended to react positively to strong operating updates but has shown mixed responses to international launches and capital-raising announcements.

Recent Company History

Over the last few months, APYX reported improving fundamentals, with Q3 2025 revenue of $12.9M, higher gross margins, and narrowed losses, alongside the U.S. launch of the AYON Body Contouring System. Subsequent news included proposed and priced equity offerings and MFDS approval plus launch of Apyx One in South Korea. Today’s preliminary 2025 revenue update extends that narrative of Surgical Aesthetics growth following AYON’s rollout and earlier international expansion.

Market Pulse Summary

The stock surged +14.9% in the session following this news. A strong positive reaction aligns with m...

Analysis

The stock surged +14.9% in the session following this news. A strong positive reaction aligns with management’s preliminary data showing total 2025 revenue of $52.7–$52.9M and roughly 17% growth in Surgical Aesthetics. Past updates, such as the Q3 2025 earnings beat, also saw favorable price responses. However, investors have recently absorbed equity financing and uneven OEM trends, which could temper enthusiasm if growth in key segments slows or further capital raises emerge.

Key Terms

GLP-1 therapies, forward-looking statements, U.S. Food and Drug Administration, Annual Report on Form 10-K, +1 more

5 terms

GLP-1 therapies medical

"This positive industry momentum is being fueled, in part, by the adoption of GLP-1 therapies..."

Drugs that mimic or boost the gut hormone GLP‑1, which helps control blood sugar and appetite by telling the body to release more insulin and feel full sooner; they are used to treat type 2 diabetes and obesity. Investors watch these therapies because they can drive large prescription sales, change healthcare spending and market share among drugmakers, and face regulatory, patent and competitive risks that directly affect company value.

forward-looking statements regulatory

"Certain matters discussed in this release... may constitute forward-looking statements..."

Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.

U.S. Food and Drug Administration regulatory

"including but not limited to the U.S. Food and Drug Administration (the “FDA”)"

The U.S. Food and Drug Administration is the federal agency that evaluates and enforces safety, effectiveness and labeling standards for medicines, medical devices, vaccines, food and related products before they reach consumers. For investors it matters because FDA approvals, warnings or recalls determine whether a product can be sold, how quickly it reaches the market and how costly compliance will be—changes that directly affect a company’s revenue, costs and stock value.

Annual Report on Form 10-K regulatory

"described in the Company’s Annual Report on Form 10-K for the fiscal year ended..."

An annual report on Form 10‑K is a required, comprehensive filing that publicly traded companies give to regulators and investors summarizing their business, results of operations, detailed financial statements reviewed by independent auditors, material risks, legal issues and management’s discussion of performance. Investors use it like a company’s year‑end report card and medical checkup: it reveals how the business made money, where it is vulnerable, and the facts needed to compare value, judge risk and make informed investment decisions.

Securities and Exchange Commission regulatory

"and the Company’s other filings with the Securities and Exchange Commission."

A national government agency that enforces rules for buying, selling and disclosing information about stocks and other investments, acting like a referee and scorekeeper for financial markets. It requires companies to share clear, regular financial and business information and investigates fraud or rule-breaking, which matters to investors because those rules and disclosures help ensure fair prices, reduce hidden risks and make it easier to compare investment choices.

AI-generated analysis. Not financial advice.

Surgical Aesthetics revenue increased approximately 38% year-over-year in the fourth quarter of 2025, including an increase of approximately 51% in the U.S. following the launch of AYON

CLEARWATER, Fla., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (Nasdaq: APYX) (the “Company” or “Apyx Medical”) the leader in surgical aesthetics marketed and sold as Renuvion^® and the AYON Body Contouring System™ (AYON), today reported preliminary revenue results for the fourth quarter and full year ended December 31, 2025.

Preliminary Fourth Quarter 2025 Revenue Summary:

• Total revenue is expected to be in the range of approximately $19.0 to $19.2 million, representing an increase of approximately 34% year-over-year.
  • Surgical Aesthetics revenue is expected to be in the range of approximately $16.6 to $16.8 million, representing an increase of approximately 38% year-over-year.
  • OEM revenue is expected to be approximately $2.4 million, representing an increase of approximately 13% year-over-year.
    

Preliminary Full Year 2025 Revenue Summary:

• Total revenue is expected to be in the range of approximately $52.7 to $52.9 million, representing an increase of approximately 10% year-over-year.
  • Surgical Aesthetics revenue is expected to be in the range of approximately $45.2 to $45.4 million, representing an increase of approximately 17% year-over-year.
  • OEM revenue is expected to be approximately $7.5 million, representing a decrease of 21% year-over-year.
    

“We are excited by AYON’s commercial launch, which delivered immediate momentum and contributed to a strong fourth quarter, including an increase of approximately 51% in revenue for our Surgical Aesthetics segment in the U.S.,” said Charlie Goodwin, President and CEO of Apyx Medical Corporation. “With Renuvion and AYON now in the market, we are well-positioned to capitalize on the expected increase in aesthetic surgical procedures in the U.S. This positive industry momentum is being fueled, in part, by the adoption of GLP-1 therapies resulting in significant patient weight loss and loose and lax skin.”

This press release includes Apyx Medical Corporation’s preliminary revenue results for the quarter and full year ended December 31, 2025. Apyx Medical plans to release its fourth quarter and full year 2025 financial results in March 2026. Actual fourth quarter and full year 2025 revenue results are subject to completion of the Company’s year-end financial closing procedures and year-end audit procedures by the Company’s independent registered public accounting firm.

Investor Relations Contact:

Jeremy Feffer, Managing Director LifeSci Advisors
OP: 212-915-2568
jfeffer@lifesciadvisors.com

About Apyx Medical Corporation:

Apyx Medical Corporation is a surgical aesthetics company with a passion for elevating people’s lives through innovative products, including its Helium Plasma Platform Technology products marketed and sold as Renuvion^® and the AYON Body Contouring System^TM in the cosmetic surgery market and J-Plasma^® in the hospital surgical market. Renuvion and J-Plasma offer surgeons a unique ability to provide controlled heat to tissue to achieve their desired results. The effectiveness of Renuvion and J-Plasma are supported by more than 90 clinical documents. The AYON Body Contouring System is an FDA-cleared, groundbreaking, surgeon-designed body contouring system that combines precision, versatility, and innovation in an all-in-one platform. It seamlessly integrates fat removal, closed loop contouring, electrosurgical capabilities and Renuvion for tissue contraction, empowering surgeons to deliver the most comprehensive body contouring treatments for patients. The Company also leverages its deep expertise and decades of experience in unique waveforms through OEM agreements with other medical device manufacturers. For further information about the Company and its products, please refer to the Apyx Medical Corporation website at www.ApyxMedical.com.

Cautionary Statement on Forward-Looking Statements:

Certain matters discussed in this release and oral statements made from time to time by representatives of the Company may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Although the Company believes that the expectations reflected in such forward-looking statements are based upon reasonable assumptions, it can give no assurance that its expectations will be achieved.

All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including but not limited to, statements regarding the Company’s anticipated public offering, including the completion of the public offering on the anticipated terms and the use of proceeds therefrom, projections of net revenue, margins, expenses, net earnings, net earnings per share, or other financial items; projections or assumptions concerning the possible receipt by the Company of any regulatory approvals from any government agency or instrumentality including but not limited to the U.S. Food and Drug Administration (the “FDA”), supply chain disruptions, component shortages, manufacturing disruptions or logistics challenges; or macroeconomic or geopolitical matters and the impact of those matters on the Company’s financial performance.

Forward-looking statements and information are subject to certain risks, trends and uncertainties that could cause actual results to differ materially from those projected. Many of these factors are beyond the Company’s ability to control or predict. Important factors that may cause the Company’s actual results to differ materially and that could impact the Company and the statements contained in this release include but are not limited to risks, uncertainties and assumptions relating to the regulatory environment in which the Company is subject to, including the Company’s ability to gain requisite approvals for its products from the FDA and other governmental and regulatory bodies, both domestically and internationally; sudden or extreme volatility in commodity prices and availability, including supply chain disruptions; changes in general economic, business or demographic conditions or trends; changes in and effects of the geopolitical environment; liabilities and costs which the Company may incur from pending or threatened litigations, claims, disputes or investigations; and other risks that are described in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024 and the Company’s other filings with the Securities and Exchange Commission. For forward-looking statements in this release, the Company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. The Company assumes no obligation to update or supplement any forward-looking statements whether as a result of new information, future events or otherwise.

FAQ

What were Apyx Medical (APYX) preliminary Q4 2025 revenues?

Preliminary Q4 2025 total revenue is expected at $19.0–$19.2M, up ~34% year-over-year.

How much did Apyx Medical's Surgical Aesthetics revenue grow in Q4 2025 (APYX)?

Surgical Aesthetics revenue is expected at $16.6–$16.8M, an increase of ~38% year-over-year; U.S. growth was ~51% after AYON launch.

What is Apyx Medical's full-year 2025 revenue guidance in the preliminary release?

Preliminary full-year 2025 total revenue is expected at $52.7–$52.9M, up ~10% year-over-year.

Why did Apyx Medical's OEM revenue change in 2025 (APYX)?

Preliminary figures show OEM revenue of ~$7.5M for 2025, a decrease of ~21% year-over-year.

When will Apyx Medical (APYX) release audited Q4 and full-year 2025 results?

The company plans to release fourth quarter and full year 2025 financial results in March 2026.